Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067347 · ClinicalTrials.gov registry record
A Global Study of the PETAL Consortium
A clinical trial of T-Cell and NK-Cell Neoplasm, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 13
- Study locations
NCT06067347 is a study of T-Cell and NK-Cell Neoplasm that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,200 participants. The trial reports 13 study locations across 12 states.
The verdict
NCT06067347, a study of T-Cell and NK-Cell Neoplasm, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
Conditions Studied
Study Locations (13)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- City of Hope - Duarte
Colorado
- University of Colorado - Denver
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- OhioHealth - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- University of Virginia - Charlottesville
South Australia
- Royal Adelaide Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067347
The ClinicalTrials.gov registry entry for NCT06067347 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-Cell and NK-Cell Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT06067347 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06067347 about?
NCT06067347 is a clinical study titled "A Global Study of the PETAL Consortium". The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize th...
What is the current status of trial NCT06067347?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2024-01-05. Estimated completion is 2028-01.
What conditions does trial NCT06067347 study?
This clinical trial studies the following conditions: T-Cell and NK-Cell Neoplasm.
Who is sponsoring clinical trial NCT06067347?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067347 being conducted?
This trial has 13 study locations across California, Colorado, Massachusetts, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.